Pharmasset (VRUS) drops 3.6% after announcing it will "discontinue all treatment" in ongoing...

|By:, SA News Editor

Pharmasset (VRUS) drops 3.6% after announcing it will "discontinue all treatment" in ongoing Phase 2b trials that involves use of its PSI-938 hepatitis drug. The company says it "detected laboratory abnormalities associated with liver function" in patients using PSI-938.